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The anticonvulsant retigabine 
suppresses neuronal KV2-mediated 
currents
Jeroen I. Stas1,2, Elke Bocksteins1, Camilla S. Jensen2, Nicole Schmitt2 & Dirk J. Snyders1
Enhancement of neuronal M-currents, generated through KV7.2-KV7.5 channels, has gained much 
interest for its potential in developing treatments for hyperexcitability-related disorders such as 
epilepsy. Retigabine, a KV7 channel opener, has proven to be an effective anticonvulsant and has 
recently also gained attention due to its neuroprotective properties. In the present study, we found that 
the auxiliary KCNE2 subunit reduced the KV7.2-KV7.3 retigabine sensitivity approximately 5-fold. In 
addition, using both mammalian expression systems and cultured hippocampal neurons we determined 
that low μM retigabine concentrations had ‘off-target’ effects on KV2.1 channels which have recently 
been implicated in apoptosis. Clinical retigabine concentrations (0.3–3 μM) inhibited KV2.1 channel 
function upon prolonged exposure. The suppression of the KV2.1 conductance was only partially 
reversible. Our results identified KV2.1 as a new molecular target for retigabine, thus giving a potential 
explanation for retigabine’s neuroprotective properties.
Epilepsy is a complex, debilitating neurological disorder affecting ~1% of the world’s population. Currently, 
management of epileptic seizures consists of pharmacotherapy; however, in ~20–30% of patients, seizure con-
trol cannot be achieved with conventional treatment strategies1,2. In addition, in many cases drug-resistant epi-
lepsy develops upon prolonged use of antiepileptic drugs (AED’s). These drawbacks have fueled the search for 
non-conventional treatments and the development of more efficient pharmacotherapy in patients with refractory 
epilepsy3–5.
Retigabine (RTG) is a novel, ‘first-in-class’ anticonvulsant drug approved for use in partial-onset seizures6,7. 
Unlike classical AED’s that mainly affect voltage-gated Na+ (NaV) channels or NMDA/GABA-neurotransmission, 
retigabine primarily targets voltage-gated K+ channels1,2. Retigabine selectively enhances the low treshold, non-
inactivating neuronal M-current that regulates spike frequency adaptation and repetitive firing6,8,9. The molec-
ular components of the M-current are the KV7.2-KV7.5 subunits encoded by KCNQ2–5 genes respectively. 
Accordingly, many mutations in the KCNQ2 and KCNQ3 genes give rise to distinct epileptic phenotypes further 
underlining the significance of M-current’s in regulating neuronal excitability10–15. Retigabine activates KV7 chan-
nels by interfering with the normal gating behavior, i.e. retigabine shifts the voltage-dependence of activation 
to hyperpolarized potentials16. As a consequence, KV7-mediated currents activate at more negative membrane 
potentials, effectively hyperpolarizing the resting membrane potential. The binding of retigabine to KV7 channels 
occurs near the pore domain and is dependent on a conserved Trp residue (KV7.2 Trp236) that is absent in the 
KV7.1 channel primarily expressed in cardiac and epithelial cells17,18. More recently, it was found that the binding 
of retigabine is dependent on the hydrogen-bonding capability of the indole nitrogen atom in the Trp residue and 
the amide carbonyl oxygen atom of retigabine19.
This general mechanism for suppression of neuronal excitability additionally makes retigabine and other KV7 
activators interesting compounds for several other hyperexcitability-related disorders such as migraine, chronic 
pain, tinnitus, and even Huntington’s disease20–23. In addition, it has been shown that retigabine has neuroprotec-
tive properties24–26. However, not all of retigabine’s effects are necessarily due to its action on KV7 channels since 
it also modulates GABAA receptors in a similar concentration range27. Due to multiple case reports of long-term 
toxicity, its clinical application is now restricted to patients for whom other anticonvulsant drugs have proved 
inadequate28–30. Whether this toxicity arises from off-target retigabine receptors or chronic activation of KV7 
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channels remains unknown. Surprisingly, despite the large structural similarities within the KV channel family, 
little effort has been made to determine whether other KV channels are modulated by retigabine7. In addition to 
this, it has not yet been investigated whether the accessory subunit KCNE2 impacts the retigabine effect on KV7 
despite the fact that KV7.2-KV7.3 channels and KCNE2 have overlapping expression patterns and described gating 
effects31,32.
Here, we performed an electrophysiological screening on members of the KV1–KV9 and KV11 subfamilies to 
investigate whether these channels are affected by retigabine. We found that retigabine inhibited all KV channels 
tested, but that this inhibition only occurred in the high μ M range, with the exception of KV2.1. Inhibition of 
KV2.1 required only low μ M concentrations and was only partially reversible. In addition, we found that the 
addition of the auxiliary subunit KCNE2 decreased the retigabine sensitivity of heterotetrameric KV7.2-KV7.3, 
but not of KV2.1, channels. These findings identify KV2.1 as an important molecular target for the action of 
retigabine and, due to KV2.1’s key role in apoptosis, could help explain the previously reported neuroprotective 
properties24–26.
Results
KCNE2 modulates retigabine sensitivity of KV7.2-KV7.3 channels. The pharmacology of KV7 chan-
nels is highly dependent on its association with auxiliary KCNE subunits33,34. Of the five known KCNE proteins, 
KCNE2 potentially interacts with the main determinants of the M-current - heteromeric KV7.2-KV7.3 chan-
nels - based on overlapping expression patterns and gating effects31,32. Hence, we co-transfected KV7.2-KV7.3 
with YFP-KCNE2 enabling us to select KCNE2-transfected cells. Retigabine potentiated KV7.2-KV7.3 currents 
in a concentration-dependent manner (Fig. 1a) by shifting the voltage-dependence of activation to hyperpo-
larized potentials (Fig. 1b) with an EC50 of 1.9 ± 0.3 μ M and a Hill coefficient of 1.4 ± 0.1 (n = 11; Fig. 1c), as 
previously reported7,16,17. Co-transfection of KCNE2 with the KV7.2-KV7.3 channel complexes did not prevent 
retigabine from potentiating the current (Fig. 1d). However, KCNE2 reduced the shift in the voltage-dependence 
of activation (Δ V) at every concentration (Fig. 1e), resulting in a right-shifted concentration-effect curve with 
an EC50 of 10.0 ± 2.2 μ M and a Hill coefficient of 1.0 ± 0.1 (n = 9; Fig. 1f). In addition, the maximal shift in the 
voltage-dependence of activation (Δ Vmax) was reduced from 39.2 ± 1.4 mV (n = 11) under control conditions to 
30.7 ± 1.1 mV (n = 9) in the KCNE2-transfected cells (see Supplementary Table S1). Thus, KCNE2 reduced the 
retigabine sensitivity of KV7.2-KV7.3 channels approximately 5-fold.
Figure 1. KCNE2 decreases the retigabine sensitivity of heterotetrameric KV7.2-KV7.3 channels. (a) Effect 
of increasing concentrations of retigabine (1–100 μ M) on KV7.2-KV7.3 currents. Retigabine potentiated the 
KV7.2-KV7.3 current in a concentration-dependent manner, and saturation occurred above 30 μ M. Voltage 
protocol is shown on top. (b) Voltage-dependence of activation. Increasing concentrations of RTG caused a 
gradual hyperpolarizing shift. (c) Concentration-effect curve plotted as the shift in the voltage-dependence of 
activation normalized to the maximal observed shift (Δ V/Δ Vmax) as function of the drug concentration.  
(d) Similar to (a) but after co-expression with KCNE2. Retigabine potentiated the KV7.2-KV7.3-KCNE2 currents 
but unlike (a) concentrations above 1 μ M had to be used. (e) Voltage-dependence of activation. KCNE2 reduced 
the hyperpolarizing shift at every drug concentration, and decreased the maximal observed shift (Δ Vmax).  
(f) Concentration-effect curve.
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Retigabine inhibits KV channels. To determine whether retigabine affected other Kv channels, we screened 
representative channels of the KV1–KV9 and KV11 subfamilies (Fig. 2). A two-step screening pulse adjusted to the 
biophysical properties of the respective channel was used. Since they cannot form homotetrameric channels at 
the plasma membrane, members of the KV5, KV6, KV8, and KV9 subfamilies where co-transfected with KV2.135. 
Retigabine inhibited all KV channels tested, though only at high μ M concentrations (> 100 μ M). However, KV2.1 
currents were inhibited at relatively low concentrations (10 μ M) (Fig. 2). Interestingly, this increased sensitivity 
was absent when KV2.1 co-assembled respectively with KV5.1, KV6.4, KV8.1, and KV9.3 subunits.
KV2.1 inhibition is voltage-dependent and only partially reversible. To gain insight into the under-
lying mechanism of KV2.1 channel inhibition, we performed a detailed biophysical characterization of retigabine 
effects. Retigabine inhibited KV2.1 currents with an IC50 of 22.0 ± 1.6 μ M and Hill coefficient of 1.6 ± 0.1 (n = 5; 
Fig. 3b). Although KCNE2 was previously found to interact with KV2.133, it did not alter the IC50 for inhibition. 
Retigabine inhibition of KV2.1-KCNE2 currents occurred with an IC50 of 16.1 ± 1.8 μ M (p = 0.056) and a Hill 
coefficient of 1.4 ± 0.2 (p = 0.384) (n = 6). No change could be observed in the voltage-dependence of inacti-
vation (triangles, Fig. 3c) or the time constants of channel opening/closing (Fig. 3d). However, retigabine did 
induce a small but significant hyperpolarizing shift of approximately 6 mV (p = 0.012), from 3.7 ± 1.5 (n = 12) to 
− 2.5 ± 1.6 mV (n = 9), in the voltage-dependence of activation (circles, Fig. 3c and Table 1). Next, we determined 
the voltage-dependence of channel inhibition (or fractional inhibition), obtained by dividing the current-voltage 
(I-V) relationships in Fig. 3e, and plotted this alongside the voltage-dependence of activation (Fig. 3f). Inhibition 
of KV2.1 displayed a clear voltage-dependency; less inhibition occurred at weak depolarizing potentials where 
only a small fraction of KV2.1 channels conducted current. 100 μ M retigabine inhibited 78.0 ± 3.4% (n = 7) of the 
current at + 60 mV while only 27.0 ± 12.4% (n = 7) inhibition occurred at − 10 mV (Fig. 3f).
Furthermore, we determined the wash-in/wash-out kinetics of KV2.1 channel inhibition at + 30 mV where 
the voltage-dependence of inhibition was maximal (see Fig. 3f). Inhibition of KV2.1 currents was only partially 
reversible and appeared to accelerate the development of channel inactivation, indicating an open-channel block 
mechanism (Fig. 4a). Inhibition of KV2.1 by 100 μ M retigabine was slow, with a τ wash-in of 89.7 ± 14.4 s (n = 10), 
on average requiring ± 10 minutes before inhibition was saturated (Fig. 4b). Recovery of inhibition was mark-
edly slower, with a τ wash-out of 574 ± 67 s (n = 8), and incomplete with only 41.8 ± 7.6% recovery in 30 minutes 
(Fig. 4d and Table 1). Recovery of inhibition was significantly different from normal rundown (p < 0.001) and 
was not dependent on the solvent: addition of 1% DMSO did not increase the rate of recovery (Fig. 4c). Next, we 
Figure 2. Retigabine inhibits most KV channels in the intermediate to high μM range. A two-step pulse 
protocol adjusted to the biophysical properties of the respective channel was used. The voltage applied is shown 
below the respective KV channel current traces. Retigabine (colored traces) inhibited all KV channels in the high 
μ M range (> 100 μ M) with exception of KV2.1, which was inhibited at relative low μ M concentrations (10 μ M).
www.nature.com/scientificreports/
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Figure 3. Retigabine inhibition of KV2.1 is voltage-dependent. (a) Typical current recordings of KV2.1 
channels to determine the activation (left) and inactivation (right) properties, before (top) and after exposure to 
100 μ M retigabine (bottom). Voltage protocols are shown on top. (b) Concentration-effect relationship of KV2.1 
inhibition. Retigabine inhibition of KV2.1 (closed circles) currents was not significantly different (p = 0.385) in 
the presence of KCNE2 (open circles). (c) Voltage-dependence of activation (circles) and inactivation (triangles) 
in absence (closed symbols) and presence (open symbols) of 100 μ M retigabine. The voltage-dependence 
of activation was obtained by plotting the normalized tail currents (I/Imax) in the activation current traces 
from panel A as function of the prepulse potential. Retigabine induced a small but significant (p = 0.012) 
hyperpolarizing shift in the voltage-dependence of activation. The voltage-dependence of inactivation, obtained 
by plotting the normalized peak current (I/Imax) at + 60 mV after a 5 s prepulse as a function of the prepulse 
potential, was not affected by retigabine. (d) Time constants of KV2.1 channel opening (≥ 0 mV) and closing  
(< 0 mV) in absence (filled circles) and presence (open symbols) of 100 μ M retigabine. (e) Current-voltage (I-V) 
relationship, obtained by plotting the current at the end of the 500 ms varying pulse as function of the voltage. 
(f) Fractional inhibition as function of the applied voltage. The fractional inhibition, obtained by dividing the 
I-V relationships in (e) displayed significantly less inhibition at weak depolarizing potentials. The dotted line 
represents the voltage-dependence of activation of KV2.1.
www.nature.com/scientificreports/
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investigated the state-dependence of inhibition to determine whether retigabine was capable of inhibiting KV2.1 
channels in their closed-state (Supplementary Fig. S1a). Application of retigabine during a 300 s pulse to − 90 mV 
(where all channels are closed) inhibited the peak and ‘end’ current at a test pulse to + 30 mV compared to the 
control (Supplementary Fig. S1a,b). However, subsequent recording of a train of pulses revealed that this degree 
of inhibition was significantly different from saturated inhibition. Interestingly, during the ‘conventional’ wash-in 
experiments the inhibition saturated within 300 s (Fig. 4b). Thus, these observations argue against efficient inhi-
bition of closed KV2.1 channels by retigabine. Evidence for this inefficient inhibition of closed KV2.1 channels 
was further strengthened when we compared the ‘peak’ and ‘end’ currents of the wash-in protocols illustrated 
in Fig. 4b (Supplementary Fig. S1c), The ‘peak’ current during the next step was always 10–15% larger than at 
the end of the previous pulse. This indicates that no significant additional inhibition developed during the 14.5 s 
interval at − 80 mV. Given the similar ‘recovery’ independent of the level of inhibition, this most likely reflects 
recovery from slow inactivation at − 80 mV.
The slow onset of inhibition combined with the incomplete recovery raised the question whether clinically 
relevant concentrations of retigabine could affect KV2.1 when the exposure time was increased. To investigate 
this, we performed ‘incubation’ experiments (illustrated in Supplementary Fig. S2a). HEK cells were trans-
fected and exposed to low concentrations of retigabine (0.1–3 μ M) for 4 hours. Interestingly, retigabine reduced 
the KV2.1 current density in a concentration-dependent manner, independent of the manipulation or solvent 
(Supplementary Fig. S2b). The current density was significantly reduced by approximately 2.5-fold after expo-
sure to 1 (p = 0.027) and 3 μ M (p = 0.024) retigabine (Supplementary Fig. S2c). To exclude the possibility that 
the reduced current densities occurred as a consequence of altered KV2.1 channel gating, we determined the 
voltage-dependence of activation for each condition, and found that it was not modified (Supplementary Fig. S2d). 
A full biophysical characterization was performed for control and exposure to 0.1% DMSO and 1 μ M retigabine, 
but no significant changes were observed (data not shown).
Retigabine inhibits native KV2.1 currents in rat hippocampal neurons. To determine whether 
the inhibition observed in an overexpression system translated to similar effects in an in vivo setting, we tested 
native KV2-mediated currents in cultured rat hippocampal neurons. Total outward currents were recorded with 
a prepulse to − 10 mV to eliminate most of the IA current, as previously described36. 100 μ M retigabine was used 
for this purpose because: 1) it caused significant inhibition of KV2-mediated currents and 2) did not substan-
tially inhibit other KV channels (see Fig. 2). The degree of inhibition was determined at the end of the 250 ms 
pulse. As expected, retigabine caused significant inhibition, 44.0 ± 3.2% at + 60 mV (n = 9), of the total outward 
current in cultured rat hippocampal neurons (Fig. 5a). To further identify the retigabine inhibited currents as 
KV2.1-mediated, we used Guangxitoxin-1E (GxTx-1E), a selective Kv2 inhibitor37. We used a concentration of 
100 nM GxTx-1E that has been reported to produce near-saturating effects on KV2-mediated currents in mice 
CA1 hippocampal neurons37. GxTx-1E caused little additional inhibition (8.2 ± 4.8%, n = 6 and p = 0.146) of the 
total outward current suggesting that retigabine inhibited the majority of KV2-mediated currents. To validate 
these results, we performed the experiments in the reverse order: KV2-mediated currents were first inhibited with 
GxTx-1E, before retigabine was applied (Fig. 5b). GxTx-1E inhibited 45.7 ± 2.0% (n = 6) of the total outward cur-
rent at + 60 mV and retigabine did not cause significant additional inhibition (6.9 ± 3.6%, n = 6 and p = 0.589). 
As an additional control, we repeated the experiments with 5 μ M tetrodotoxin (TTX) in the bathing solution, 
in order to block NaV channels (Supplementary Fig. S3). Retigabine still inhibited a major component of the 
total outward current in the presence of extracellular TTX, with little additional inhibition caused by GxTx-1E 
(n = 3)(Supplementary Fig. S3a). The normalized current-voltage relationships confirmed these observations. 
When KV2-mediated currents were not first inhibited with GxTx-1E, retigabine inhibited a major component 
of the total outward current (Fig. 5c,d and Supplementary Fig. S3c). Interestingly, as observed for the retigabine 
Activation Inactivation
V1/2 k n V1/2 k n
KV2.1 3.7 ± 1.5 8.7 ± 0.4 12 − 21.8 ± 1.0 6.2 ± 0.3 7
100 μ M RTG − 2.5 ± 1.6 10.0 ± 1.4 9 − 24.2 ± 1.6 5.9 ± 0.4 10
RTG incubation
Control 3.8 ± 1.0 9.0 ± 0.5 14 − 21.4 ± 2.6 5.4 ± 0.2 5
0.1% DMSO 1.9 ± 1.8 8.3 ± 0.3 11 − 22.8 ± 3.0 5.60.2 5
0.1 μ M RTG 4.9 ± 1.0 8.8 ± 0.3 12
0.3 μ M RTG 3.9 ± 1.5 8.8 ± 0.5 13
1 μ M RTG 6.3 ± 1.6 8.9 ± 0.6 12 − 17.0 ± 1.5 5.8 ± 0.4 5
3 μ M RTG 6.7 ± 1.2 8.0 ± 0.4 12
Inhibition Kinetics
τwash-in (s) τwash-out (s) % Inhibition % Recovery n
100 μ M RTG 89.7 ± 14.4 574 ± 67 80.8 ± 2.7 41.8 ± 7.6 8
Table 1.  Biophysical properties of KV2.1. V1/2, midpoint of activation or inactivation; k, slope factor; n, 
number of cells; τ wash-in, the rate of inhibition; τ wash-out, the rate of recovery. Values significantly different from 
the control values are shown in bold (p < 0.05).
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inhibition of KV2.1 in HEK cells, retigabine inhibited the total outward current in a voltage-dependent manner 
with decreased sensitivity at weak depolarizing potentials.
Discussion
Enhancement of KV7 channel activity by retigabine provides a general mechanism for suppression of multiple 
hyperexcitability-related disorders such as epilepsy, chronic pain and tinnitus20–22. Our results illustrate that the 
auxiliary KCNE2 subunits reduced the retigabine sensitivity of KV7.2-KV7.3 by approximately 5-fold. Although 
the role of KCNE2 in the nervous system and its interaction with KV7.2-KV7.3 channels remain controversial, 
the potential of KCNE2 to modulate KV channel pharmacology is well established31,33. The interaction between 
KCNE2 and KV7.2-KV7.3 channels alters the biophysical properties modestly32. Our study showed that KCNE2 
reduced the retigabine sensitivity of KV7.2-KV7.3 channels, further supporting the idea that KCNE2 can inter-
act with these KV7.2-KV7.3 channels. However, we did not observe the previously reported KCNE2-induced 
Figure 4. Inhibition of KV2.1 current by retigabine is only partly reversible. (a) Representative KV2.1 
current traces (black) at + 30 mV (left). The scaled current traces are shown in the right panel. Retigabine (grey) 
inhibited approximately 80% of the current but inhibition was poorly recovered 30 minutes after removal of 
retigabine (dotted). The ‘apparent’ acceleration of the inactivation process seen in the scaled current traces most 
likely reflects open-channel block by retigabine. (b) Plot of a representative wash-in/wash-out experiment. 
Inhibition of the KV2.1 current occurred slowly, typically requiring 5–10 minutes to achieve saturation. 
Inhibition of KV2.1 currents was poorly reversible and occurred extremely slow. (c) Bar chart illustrating the 
degree of current (I/Ic), with I the current at a given condition and Ic the control condition. KV2.1 inhibition 
was poorly reversible, independent of the solvent, and significantly different from current rundown. *Indicates 
statistical significance (p < 0.05).
www.nature.com/scientificreports/
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Figure 5. Retigabine inhibits the KV2-mediated component of the outward current in cultured rat 
hippocampal neurons. (a) Representative current traces from cultured rat hippocampal neurons. 100 μ M 
retigabine inhibited the outward current and the RTG-sensitive current was obtained after subtraction. 100 nM 
Guangxitoxin-1E (GxTx), i.e. selective KV2 inhibitor, was used to confirm the inhibition of KV2-mediated 
current by retigabine. Retigabine inhibited a major component of delayed rectifier current, with little inhibition 
caused by GxTx (b) similar to (a) although the KV2-mediated current was first inhibited with GxTx before 
applying retigabine. Inhibition of the KV2-mediated component of the current by GxTx resulted in little 
inhibition of retigabine. However, retigabine still inhibited a fast activating and inactivating current.  
(c,d) Current-voltage relationship, obtained by plotting the total outward current at the end of the 250 ms step as 
function of the voltage with retigabine (c) or GxTx (d) initial exposure. (e,f) Fractional inhibition as a function 
of the applied voltage. As observed in HEK cells (Fig. 3f), retigabine (e) had a voltage-dependence of inhibition 
that could be abolished after subsequent exposure to GxTx. Panel (f) is similar to (e) but with initial exposure to 
GxTx. Lines represent the voltage-dependence of activation fitted with the Boltzmann equation.
www.nature.com/scientificreports/
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changes in the biophysical properties. In our experiments, KCNE2 had the tendency to hyperpolarize the 
voltage-dependence of activation. Even though KCNE2 reduced the retigabine sensitivity of KV7.2-KV7.3 chan-
nels, it still had some effect within the clinical plasma concentration range as illustrated in Fig. 6a where we show 
the concentration-effect curves together with the retigabine plasma concentration range6,38–42.
By demonstrating that clinically relevant retigabine concentrations inhibited KV2-currents, presumably 
through an open channel block mechanism, both in HEK cells and hippocampal neurons (Fig. 6b), our findings 
indicate that KV2 channels might represent an important ‘off-target’ receptor responsible for some of retigabine’s 
(adverse) effects. Although acute exposure of KV2.1 channels to retigabine resulted in inhibition at concentra-
tions above the clinical range (blue circles Fig. 6b), the prolonged incubation experiments (bars Fig. 6b) revealed 
a strong reduction of the KV2.1 current density at clinical, and even sub-clinical concentrations of retigabine. 
As a result, retigabine might exert a significant effect on KV2.1 channels in vivo. Pharmacological suppression 
of KV2 channels results in either an increase or decrease of neuronal excitability, as previously shown with the 
KV2-selective inhibitor GxTx-1E37. GxTx-1E inhibits between 60–80% of the total delayed rectifier current in rat 
superior cervical ganglion neurons and mouse hippocampal CA1 neurons. This results in an increased initial fir-
ing frequency but depresses maintained firing. 100 nM GxTx-1E only inhibited ~50–55% of total outward current 
in our experiments. This discrepancy most likely arises from differences in the age of the hippocampal neurons 
used: Liu and Bean performed recordings on acutely dissociated hippocampal neurons while our recordings were 
performed on hippocampal neurons that were cultured for 10–15 days in vitro.
KV2.1 channel expression is rather ubiquitous and serves major physiological functions in the central nerv-
ous system and (neuro)endocrine cells43,44. KV2.1 channels constitute the major delayed rectifier current in hip-
pocampal neurons, and targeted deletion of KV2.1 results in neuronal and behavioral hyperexcitability37,45,46. The 
expression pattern of KV2.1 channels is intriguing, in that they form cell-surface clusters at the soma, proximal 
dendrites and the axon initial segment, not only in cultured hippocampal neurons and intact brain but also in 
transfected HEK cells47,48. Interestingly, within the clusters, KV2.1 channels are inactive, i.e. gating charge move-
ment of the voltage sensing domains was detected without measurable ionic currents, and upon dispersal, the 
ionic current is regained. Within the micro-domain of the cluster, KV2.1 channels are in close proximity to the 
endoplasmatic reticulum (ER) and induce the formation of ER-plasmamembrane junctions49–51. Thus, it was 
suggested that KV2.1 cell surface clusters are insertion platforms for ER-membrane trafficking52. Clustering of 
KV2.1 is highly dependent on the phosphorylation state of the channel and directly linked to underlying neuronal 
activity. This means that hyperexcitability, as observed during epileptic seizures, promotes dephosphorylation 
of KV2.1 through a Ca2+/calcineurin-dependent mechanism which leads to increased KV2.1 activity and KV2.1 
declustering36,53,54. Interestingly, KV2.1 clusters can also be dispersed pharmacologically. When hippocampal neu-
rons are exposed to glutamate, rapid KV2.1 declustering occurs55. Due to the fact that retigabine inhibited KV2.1 
currents in a poorly reversible manner, both in HEK cells and hippocampal neurons, KV2.1 trafficking might be 
affected upon retigabine exposure. One could speculate that loss of functional KV2.1 channels at the cell surface, 
due to increased endocytosis or changed clustering pattern, might contribute to retigabine’s poorly reversible 
inhibition of Kv2.1 currents. However, using live-cell imaging of GFP-tagged KV2.1, we did not observe a change 
in the KV2.1 localization within 30 min after exposure to retigabine (data not shown). Interestingly, KV2.1 current 
Figure 6. Molecular pharmacology on KV2 and KV7 channels in HEK cells compared with retigabine 
plasma concentrations. (a) Concentration-effect relationship of retigabine potentiation on KV7.2-KV7.3 
currents in the absence (filled circles) and presence (open circles) of KCNE2. The grey bar represents the 
plasma concentration range, minimum (0.65 μ M) to maximum (6.6 μ M), in patients treated with 600–1200 mg 
retigabine/day38–42. Although KCNE2 shifted the concentration-effect curve, KV7.2-KV7.3 current potentiation 
was not fully prevented in the plasma concentration range. (b) Concentration-effect relationship of KV2.1 
inhibition in absence (blue, filled circles) and presence (blue, open circles) of KCNE2, obtained from direct 
perfusion of retigabine on the Kv2.1 channels. The light grey bar represents the plasma concentration range as 
in (a). Black, white, dark grey and striped bar represent the x-fold reduction in KV2.1 current density obtained 
from the retigabine incubation experiments. Although little direct KV2.1 inhibition occurred, maximal 
suppression of the KV2.1 current density occurred in the plasma concentration range.
www.nature.com/scientificreports/
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densities were reduced with much lower retigabine concentrations (0.1–3 μ M) upon prolonged exposure. In this 
case, the reduced KV2.1 current density might simply reflect the population of KV2.1 channels that were not 
inhibited by retigabine as the gating and trafficking (data not shown) properties were not modified. In addition, it 
cannot be excluded that the observed reduction in KV2.1 current density is (partially) caused by a drug metabolite 
of retigabine. On the other hand, retigabine’s hydrophobic nature suggests that it might reside in the lipid bilayer 
or bind to a hydrophobic region in the KV2.1 channel. Although this could help explain the poor reversibility of 
KV2.1 current inhibition upon wash-out, it seems rather unlikely, because: 1) increased solvent concentrations 
had no significant effect on the reversibility of inhibition (Fig. 4c), and 2) retigabine’s action on KV7 channels was 
always fully reversible. An interesting future direction will be to further investigate the underlying mechanism of 
this poorly reversible reduction in KV2.1 current densities.
Interestingly, KV2.1 might be involved in the neuroprotective properties of retigabine that have been described 
more recently, especially due to the key role of KV2.1 in apoptosis56,57. Upon neuronal injury, KV2.1-currents are 
increased through de novo insertion of channels in the plasma membrane and subsequent decrease of intracel-
lular [K+] levels promoting activation of the apoptotic cascade58. The extent of cell death can be reduced when 
the pro-apoptotic KV2.1 current is pharmacologically inhibited59. Therefore, retigabine might prevent apoptosis 
through inhibition of KV2.1 currents, thus promoting cell survival. However, retigabine was found to promote 
neuroprotection by diminishing excitotoxicity through suppression of hyperexcitability by KV7 channel activa-
tion24–26. Thus, retigabine might promote neuroprotection in neurons through its concerted action on KV2 and 
KV7 channels.
In conclusion, we found that the retigabine sensitivity of KV7 channels is reduced by the auxiliary KCNE2 
subunit. In addition, retigabine inhibited KV2.1 channels most likely through an open-channel block mechanism 
in a poorly reversible manner at clinically relevant concentrations.
Materials and Methods
Molecular biology. Human KV1.5 (GenBank Accession Number NM_002234), KV2.1 (NM_004975), KV3.1 
(NM_004976), KV4.2 (NM_012281), KV5.1 (NM_002236), KV6.4 (NM_172347), KV8.1 (NM_014379) and KV11.1 
(NM_000238), as well as mouse KV9.3 (NM_173417), were subcloned in the eGFP-N1 vector (Clontech, Palo 
Alto, CA, USA). Human KV7.1 (NM_000218), KV7.2 (NM_172107), KV7.3 (NM_004519), KCNE2 (NM_172201) 
and YFP-KCNE2 were subcloned in the pBK/CMV vector as described previously60.
Transient transfection and cell culture. HEK293 cells were cultured in 60 mm cell culture dishes filled 
with 4 ml culture medium - consisting of Dulbecco’s modified Eagle’s medium supplemented with 10% horse 
serum, 1% penicillin/streptomycin and 1% non-essential amino acids–under physiological conditions (37 °C and 
5% CO2). HEK293 cells were transiently transfected with 0.05–5 μ g cDNA of the respective channel together with 
the GFP transfection marker using Lipofectamine2000 (Invitrogen, San Diego, CA, USA), according to the manu-
facturer’s instructions. To obtain the characteristic KV7.2-KV7.3 currents both KV subunits were co-transfected in 
a 1:1 molar ratio. Co-transfection with KCNE2 was performed in 1:1:4 and 1:4 molar ratios for KV7.2-KV7.3 and 
KV2.1 channels, respectively. The amount of cDNA was kept identical between the–KCNE2 and + KCNE2 experi-
ments by addition of empty vector cDNA. A C-terminal YFP-KCNE2 construct was used to allow for selection of 
KCNE2-transfected cells. The YFP-KCNE2 behaved similarly to the untagged KCNE2. 16–24 h after transfection, 
HEK293 cells were dissociated with trypsine and transferred to the patch-clamp set-up for electrophysiological 
analysis.
The retigabine incubation experiments were performed on HEK293 cells transfected with 10 ng KV2.1 over 
48 h. 24 h post-transfection, HEK293 cells were either exposed to normal medium (control) containing 0.1% 
DMSO (vehicle control) or 0.1, 0.3, 1 or 3 μ M retigabine for 4 h. After the 4 h exposure, the incubation medium 
was removed and fresh medium was added to the transfected HEK293 cells. Thus, at the moment of electrophys-
iological analysis (48 h post-transfection), no retigabine was present in the recording solution.
Primary cultures of rat hippocampal neurons. All use of animals was approved by the institutional 
animal care and use committee of the University of Copenhagen. All experiments were performed in accord-
ance with the relevant guidelines and regulations. Primary cultures of rat hippocampal neurons were obtained as 
described previously61. In summary, whole brains were removed from E18/E19 rat embryos. Hippocampi were 
dissected, and the cells dissociated and cultured on poly-L-lysine treated coverslips that were placed upon an 
astrocyte feeder layer. Hippocampal neurons were cultured 10–15 days in vitro and afterwards analyzed with the 
patch–clamp technique.
Electrophysiology. Whole-cell ionic currents were recorded as previously described62. In summary, 
whole-cell current recordings were performed at room temperature (20–22 °C) utilizing an Axopatch-200B/700B 
amplifier (Axon instruments, Union City, CA, USA), sampled at a 1–10 kHz frequency using a Digidata 1440/1550 
acquisition system (Axon instruments) and filtered with a low-pass Bessel filter. The pClamp10 software (Axon 
instruments) controlled the command voltages and managed the data storage. HEK293 cells were continuously 
perfused with extracellular solution (ECS) containing (in mM): 145 NaCl, 4 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES and 
10 Glucose, adjusted to a pH of 7.35 with NaOH. Patch pipettes (1.5–2.5 MΩ) were pulled from borosilicate glass 
capillaries, heat polished and filled with an intracellular solution (ICS) containing (in mM): 110 KCl, 5 K2ATP, 
5 K4BAPTA, 2 MgCl2 and 10 HEPES, pH adjusted to 7.2 with KOH. ICS and ECS solutions were used to record 
in HEK293 cells as well as in native hippocampal neurons. Where mentioned, 5 μ M TTX was added to the ECS 
solution to inhibit native Na+ currents. When leak currents exceeded 10% of the total ionic current or voltage 
errors at the highest used potential exceeded the cut-off value of 5 mV (after series resistance compensation), cells 
were excluded from analysis.
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Drug solutions. All drug solutions were applied to the HEK293 cells using a fast perfusion system (ALA 
scientific Instruments, Farmingdale, NY, USA). Control recordings were obtained with fast perfusion of ECS 
solution. Retigabine (Alomone Labs, Jerusalem, Israel) was dissolved in DMSO to obtain a stock solution of 
100 mM. The working concentrations (0.1–300 μ M) were obtained by diluting the stock solution in ECS solution. 
Guangxitoxin–1E (Alomone Labs) and TTX (Sigma-Aldrich, Schnelldorf, Germany) were dissolved and diluted 
in ECS solution to obtain the stock (100 μ M and 5 mM) and working (100 nM and 5 μ M) solutions.
Data analysis and statistics. The Hill equation: 1 − y = 1/(1 + (EC50/[D])nH), was fitted to concentration- 
effect curves to obtain a relative measurement of drug affinity with EC50 the concentration that induces 50% 
of the effect and nH the Hill coefficient. For Kv7 channels the effect is defined as the induced shift in the volt-
age–dependence of activation normalized to the maximal shift (i.e. Δ V/Δ Vmax) while for Kv2.1 the degree of 
current inhibition (%) was plotted. The Boltzmann equation: y = 1/(1 + exp (−(V − V1/2)/k)), was applied to fit 
the voltage–dependence of (in)activation, where V represents the applied potential, V1/2 the voltage where 50% of 
the channels are (in)activated, and k the slope factor. Results were reported as the mean value ± S.E.M. Standard 
t–test or the Mann–Whitney Rank Sum test were used to determine whether the results achieved statistical sig-
nificance. Statistical significance was defined as P < 0.05. Pulse protocols were adjusted to match the biophysical 
properties of the respective Kv channel and are illustrated throughout the figures.
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